NexGen Health has announced the official launch of its exclusive Cerebrolysin IV Therapy Program, a cutting-edge neurorecovery protocol designed to support brain health, enhance cognitive function, and provide personalized care for patients managing complex neurological conditions.
Led by board-certified physicians specializing in regenerative medicine, physical medicine, interventional pain, and functional medicine, NexGen Health’s Cerebrolysin program is centered around a personalized 10-treatment intravenous protocol. Patients are carefully evaluated and monitored throughout the process, which is designed to support recovery from stroke, traumatic brain injury, cognitive decline, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
Cerebrolysin is a neuropeptide-based therapy containing small proteins and amino acids that mimic naturally occurring neurotrophic factors – the compounds that support neuron growth and survival. Unlike many therapies, Cerebrolysin is capable of crossing the blood-brain barrier, enabling direct access to brain tissue. Its clinical effects include stimulation of neuroplasticity, reduction of neuroinflammation, improved synaptic function, and protection against oxidative stress.
Each treatment begins with medical clearance through NexGen Health’s clinical team. Once approved, patients receive daily or alternate-day IV infusions of Cerebrolysin over a 10-day period, with treatment sessions typically lasting 20 to 45 minutes. The peptides are rapidly absorbed and transported to brain tissue, where they deliver neuroprotective and regenerative effects through a variety of scientifically validated pathways.
The protocol is tailored to patient-specific goals and may be repeated or adjusted based on progress. Many patients report encouraging outcomes within the first cycle, with ongoing improvements in cognitive clarity, focus, motor function, and neurologic resilience.
